Abstract
The modern era of research on the nature of adenosine receptors began in the early seventies. At that time the stimulatory effect of adenosine on formation of cyclic AMP in brain slices and blockade by xanthines, such as caffeine and theophylline, was discovered (Sattin and Rall, 1979). The class of adenosine receptors that are coupled to adenylate cyclase in an inhibitory manner have become known as A1-receptors, while the class of adenosine receptors that are coupled to adenylate cyclase in a stimulatory manner have become known as A2-receptors. The rank order of potencies for certain agonists differed at A1- and A2-receptors and it was suggested that rank order of potencies at 5’-N’ ethylcarboxamidoadenosine (NECA), 2-chloroadenosine, N6-R-phenylisopropyladenosine and N6-S-phenylisopropyladenosine might be useful for definition of the class of adenosine receptor involved in physiological responses (see Daly, 1982). This series of agonists has not proven to be entirely satisfactory and more definitive series of selective agonists and antagonists have been and are being sought. The lack of complete correspondence of rank orders of potencies of agonists in certain physiological systems to that expected of A1 receptors coupled to adenylate cyclase has led to the proposal of an A3-receptor, which is localized in presynaptic nerve terminals and which serves to inhibit neurotransmitter release (Ribeiro and Sebastião, 1986). In the synaptic terminals a variety of evidence suggests that the receptor is coupled not to adenylate cyclase, but instead in an inhibitory manner to calcium channels or calcium function. There also is evidence for adenosine receptors that are coupled in a stimulatory manner to potassium channels in brain and heart (see Fredholm and Dunwiddie, 1988). At present the adenosine receptors coupled to calcium and potassium channels are perhaps best still treated as subclasses of A1 receptors, since unambiguous paradigms for distinguishing these receptors from A1 receptors coupled to adenylate cyclase have not been developed.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Bridges, A.J., Moss, W.H., Szotek, D.L., Trivedi, B.K., Bristol, J.A., Hoffner, T.G., Bruns, R.F. and Downs, D.A. (1987) J. Med. Chem. 30, 1709–1711.
Bridges, A.J., Bruns, R.F., Ortwine, D.F., Priebe, S.R., Szotek, D.L. and Trivedi, B.K. (1988) J. Med. Chem. 31, 1282–1285.
Bruns, R.F. (1980) Can. J. Physiol. Pharmacol. 58, 673–691.
Bruns, R.F., Daly, J.W. and Snyder, S.H. (1980) Proc. Natl. Acad. Sci. USA 77, 5547–5551.
Bruns, R.F. (1981) Biochemical Pharmacol. 30, 325–333.
Bruns, R.F., Daly, J.W. and Snyder, S.H. (1983) Proc. Natl. Acad. Sci. USA 80, 2077–2080.
Bruns, R.F., Lu, G.H. and Pugsley, T.A. (1986) Mol. Pharmacol. 29, 331–346.
Bruns, R.F., Lu, G.H. and Pugsley, T.A. (1987a) In “Topics and Perspectives in Adenosine Research. Eds., E. Gerlach and B.F. Becker. Springer-Verlag Berlin Heidelberg, pp. 59–73.
Bruns, R.F., Fergus, J.H., Badger, E.W., Bristol, J.A., Santay, L.A., Hartman, J.D., Hays, S.J. and Huang, C.C. (1987b) Naunvn-Schmiedeberg’s Arch. Pharmacol. 335, 59–63.
Choi, O.H., Shamim, M.T., Padgett, W.L. and Daly, J.W. (1988) Life Sci. 43, 387–398.
Cristalli, G., Franchetti, P., Grifantini, M., Vittori, S., Klotz, K.-N. and Lohse, M.J. (1988) J. Med. Chem. 31, 1179–1183.
Daly, J.W. (1982) J. Med. Chem. 25, 197–207.
Daly, J.W., Butts-Lamb, P. and Padgett, W. (1983) Cellular Mol. Neurobiology 3, 69–80.
Daly, J.W., Padgett, W., Shamim, M.T., Butts-Lamb, P. and Waters, J. (1985) J. Med. Chem. 28, 487–492.
Daly, J.W., Padgett, W. and Shamim, M.T. (1986a) J. Med. Chem. 29, 1305–1308.
Daly, J.W., Padgett, W., Thompson, R.D., Kusachi, S., Bugni, W.J. and Olsson, R.A. (1986b) Biochem. Pharmacol. 35, 2467–2481.
Daly, J.W., Padgett, W. and Shamim, M.T. (1986c) J. Med. Chem. 29, 1520–1524.
Daly, J.W., Hong, O., Padgett, W.L., Shamim, M.T., Jacobson, K.A. and Ukena, D. (1988a) Biochemical Pharmacol. 37, 655–664.
Daly, J.W., Padgett, W.L. and Eger, K. (1988b) Biochemical Pharmacol. 37, 3749–3753.
Dragunow, M. and Faull, R.L.M. (1988) Trends Pharmacological Sci. 9, 193–194.
Evoniuk, G., Jacobson, K.A., Shamim, M.T., Daly, J.W. and Wurtman, R.J. (1987a) J. Pharmacol. Exper. Therap. 242, 882–887.
Evoniuk, G., Von Borstel, R.W. and Wurtman, R.J. (1987b) J. Pharmacol. Exp. Therap. 240, 428–432.
Fredholm, B.B., Jacobson, K.A., Jonzon, B., Kirk, K.L., Li, Y.D. and Daly, J.W. (1987) J. Cardiovascular Res. 9, 396–400.
Fredholm, B.B. and Dunwiddie, T.V. (1988) Trends Pharmacological Sci. 9, 130–134.
Hamilton, H.W., Ortwine, D.E., Worth, D.F., Badger, E.W., Bristol, J.A., Bruns, R.E., Haleen, S.J. and Steffen, R.P. (1985) J. Med. Chem. 28, 1071–1079.
Hamilton, H.W., Taylor, M.D., Steffen, R.P., Haleen, S.J. and Bruns, R.F. (1987) Life Sci. 41, 2295–2302.
Heller, L.J. and Olsson, R.A. (1985) Am. J. Phvsiol. 248, H907-H913.
Hutchison, A.J., Oei, H.H., Chai, G.R. and Williams, M. (1989) CGS 21680, an A2 selective adenosine (ADO) receptor agonist with preferential hypotensive activity. FASEB J. 3, A281.
Jacobson, K.A., Kirk, K.L., Padgett, W.L. and Daly, J.W. (1985a) J. Med. Chem. 28, 1334–1340.
Jacobson, K.A., Kirk, K.L., Daly, J.W., Jonzon, B., Li, Y.-O. and Fredholm, B.B. (1985b) Acta Phvsiol. Scand. 125, 341–342.
Jacobson, K.A., Ukena, D., Kirk, K.L. and Daly, J.W. (1986) Proc. Natl. Acad. Sci. USA 83, 4089–4093.
Jacobson, K.A., de la Cruz, R., Schulick, R., Kiriasis, L., Padgett, W., Pfleiderer, W., Kirk, K.L., Neumeyer, J.L. and Daly, J.W. (1988) Biochemical Pharmacol. 37, 3653–3661.
Jacobson, K.A., Kiriasis, L., Barone, S., Bradbury, B.J., Kammula, U., Campagne, J.M., Secunda, S., Daly, J.W., Neumeyer, J.L. and Pfleiderer, W. (1989) Sulfur-containing xanthine derivatives as selective antagonists at Ai-adenosine receptors. J. Med. Chem. 32, 1873–1879.
Katims, J.J., Annau, Z. and Snyder, S.H. (1983) J. Pharmacol. Exp. Therap. 227, 167–173.
Kurtz, A. (1987) Adenosine stimulates guanylate cyclase activity in vascular smooth muscle cells. J. Biol. Chem. 262, 6296–6300.
Linden, J. and Delahunty, T.M. (1989) Trends Pharmacological Sci. 10, 114–120.
Lohse, McJ., Klotz, K.-N., Diekmann, E., Friedrich, K. and Schwabe, U. (1988a) Eur. J. Pharmacol. 156, 157–160.
Lohse, M.J., Klotz, K.-N., Schwabe, U., Cristalli, G., Vittori, S. and Grifantini, M. (1988b) Naunvn-Schmiedeberg’s Arch. Pharmacol. 337, 687–689.
Londos, C., Cooper, D.M.F. and Wolff, J. (1980) Proc. Natl. Acad. Sci. USA 77, 2551–2554.
Martinson, E.A., Johnson, R.A. and Wells, J.N. (1987) Mol. Pharmacol. 31, 247–252.
Matsuda, A. and Ueda, T. (1987) Nucleosides Nucleotides 6, 85–94.
Mikkelsen, E.J. (1978) J. Clin. Psychiatry 39, 732–736.
Moos, W.H., Szotek, D.S. and Bruns, R.F. (1985) J. Med. Chem. 28, 1383–1384.
Munshi, R., Clanachan, A.S. and Baer, H.P. (1988) Biochemical Pharmacol. 37, 2085–2089.
Nimit, Y., Law., J. and Daly, J.W. (1982) Biochem. Pharmacol. 31, 3279–3287.
Oei, H.H., Ghai, G.R., Zoganas, H.C., Stone, G.A., Zimmerman, M.B., Field, F.P. and Williams, M. (1988) J. Pharmacol. Exp. Therap. 247, 882–888.
Ohga, Y. and Daly, J.W. (1977) Biochim. Biophvs. Acta 498, 46–60.
Olsson, R.A., Kusachi, S., Thompson, R.D., Ukena, D., Padgett, W. and Daly, J.W. (1986) J. Med. Chem. 29, 1683–1689.
Paton, D.M. (1980) J. Pharm. Pharmacol. 32, 133–135.
Ribeiro, J.A. and Sebastiao, A.M. (1986) Prog. Neurobiology 26, 179–209.
Sattin, A. and Rail, T.W. (1970) Mol. Pharmacology 6, 13–23.
Schimmel, R.J. and Elliott, M.E. (1988)Biochem. Biophvs. Res. Commun. 152, 886–892.
Seale, T.W., Abla, K.A., Shamim, M.T., Carney, J.M. and Daly, J.W. (1988) Life Sci. 43, 1671–1684.
Shamim, M.T., Ukena, D., Padgett, W.L., Hong, O. and Daly, J.W. (1988) J. Med. Chem. 31, 613–617.
Shamim, M.T., Ukena, D., Padgett, W.L. and Daly, J.W. (1989) J. Med. Chem. 32, 1231–1237.
Smellie, F.W., Davis, C.W., Daly, J.W. and Wells, J.N. (1979) Life Sci. 24, 2475–2482.
Snyder, S.H., Katims, J.J., Annau, Z., Bruns, R.F. and Daly, J.W. (1981) Proc. Natl. Acad. Sci. USA 78, 3260–3264.
Trivedi, B.F., Bristol, J.A., Bruns, R.F., Haleen, S.J. and Steffen, R.P. (1988) J. Med. Chem. 31, 271–273.
Trivedi, B.K., Bridges, A.J., Patt, W.C., Priebe, S.R. and Bruns, R.F. (1989) J. Med. Chem. 32, 8–11.
Ukena, D., Shamim, M.T., Padgett, W. and Daly, J.W. (1986) Life Sci. 39, 743–750.
Ukena, D., Olsson, R.A. and Daly, J.W. (1987a) Can. J. Physiol. Pharmacol. 65, 365–376.
Ukena, D., Padgett, W.L., Hong, O., Daly, J.W., Daly, D.T. and Olsson, R.A. (1987b) FEBS Lett. 215, 203–208.
Wiklund, N.P., Gustafsson, L.E. and Lundin, J. (1985) Acta Physiol. Scand. 125, 681–691.
Williams, M. (1987) Ann. Rev. Pharmacol. Toxicol 27, 315–345.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1990 Springer-Verlag New York Inc.
About this paper
Cite this paper
Daly, J.W. (1990). Adenosine Agonists and Antagonists. In: Jacobson, K.A., Daly, J.W., Manganiello, V. (eds) Purines in Cellular Signaling. Springer, New York, NY. https://doi.org/10.1007/978-1-4612-3400-5_1
Download citation
DOI: https://doi.org/10.1007/978-1-4612-3400-5_1
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4612-7996-9
Online ISBN: 978-1-4612-3400-5
eBook Packages: Springer Book Archive